Primary : To evaluate the efficacy of sirolimus assessed by the incidence of biopsy-confirmed
acute rejection episode at 6 months after transplantation in Korean renal transplantation
recipients.
Secondary :
1. To evaluate the safety of sirolimus over 12 months after transplantation in Korean renal
transplantation recipients.
2. To evaluate graft function, patient survival and graft survival at 6 and 12 months after
transplantation, and to investigate the incidence of biopsy-confirmed acute rejection
episode at 12 months after transplantation.